Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 95

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 95
---
 or fraud in connection with any business entity; or                    |

| ● | Being subject of or party to any sanction or order, not subsequently                                                                 
 reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, 
 entity, or organization that has disciplinary authority over its members or persons associated with a member.                        |

Director Independence

Our Board is currently composed of four (4) members. Our Common Stock is not currently listed for trading on a national securities exchange and, as such, we are not subject to any director independence standards. We determined that with the exception of Inna Martin, our Chief Operating Officer and Daniel Bartal, all other members of our Board of Directors are considered independent directors as that term is defined by NASDAQ Marketplace Rule 5605(a)(2). In assessing the independence of the directors, the Board considers any transactions, relationships and arrangements between our Company and our directors or their affiliated companies. This review is based primarily on responses of the directors to questions in a director and officer questionnaire regarding employment, business, familial, compensation and other relationships with our Company or our management.

Term of Office

Our directors are appointed for to hold office until the next annual general meeting of our stockholders or until removed from office in accordance with our bylaws. Our officers are appointed by our Board and hold office until removed by the Board.

Code of Ethics

Our Board of Directors has not adopted a code of ethics but plans to do so in the near future.

<div align='center'>58

EXECUTIVE COMPENSATION</div>

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by, or paid to our Chief Executive Officer and the other most highly compensated executive officer serving as executive officers and whose compensation exceeded $100,000 during fiscal year ended December 31, 2024 and 2023 as determined by Regulation S-K, Item 402 (each a “Named Executive Officer”).

<div align='center'>SUMMARY COMPENSATION TABLE</div>

| Name and principal position |     | Year |     | Salary 
 ($)    |         |     | Bonus 
 ($)   |   |     | Stock  
 Awards 
 ($)    |   |     | Option 
 Awards 
 ($)(1) |           |     | Non-Equity     
 Incentive Plan 
 Compensation   
 ($)            |   |     | Nonqualified 
 Deferred     
 Compensation 
 Earnings     
 ($)          |   |     | All Other